The H. polymorpha platform has successfully been applied to the process development of pharmaceuticals, such as food additives and feed additives, and for the production of enzymes. Its worldwide recognition as a safe and reliable expression system that is robust and scalable has made H. polymorpha a highly competitive production system for a broad range of industrial proteins.

Hansenula polymorpha technology for highly immunogenic vaccines

The worldwide use of Crucell’s H. polymorpha-based Hepavax-Gene^® against hepatitis B demonstrates the successful application of this expression system for the production of highly immunogenic and safe vaccines.  

The H. polymorpha platform has been widely used in the development of feed and food products, enzymes and vaccines. Several H. polymorpha-derived products such as food and feed additives are registered worldwide or are in clinical trials, such as interferon a2. Crucell has a GMP production facility for the manufacture of it’s Hepavax-Gene^® vaccine which is approved, marketed and used in many countries for prevention against hepatitis B.